This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge

PARSIPPANY, NJ. ( TheStreet) -- Pacira Pharmaceuticals (PCRX - Get Report) received U.S. approval to sell a long-acting post-surgical painkiller but now must convince hospitals that using the new drug can help patients and save them money.

Shares of Pacira rose as much as 20% to over $12 in Monday's pre-market session on news of the U.S. Food and Drug Administration approval of Exparel was released. The Pacira stock pop didn't last long. Shares are up just 3% to $10.48 in mid-morning trading.

The volatility in Pacira trading Monday follows a typical pattern in which investors move quickly from loving a company seeking drug approval to being wary of the same company once the approved drug has to be launched commercially.

In Pacira's case, the post-approval selling may be accelerated by the additional challenge facing the company of selling Exparel to hospitals, which can be a more complicated and lengthy process than selling drugs to individual doctors.

Exparel is a long-acting formulation of the painkiller bupivicaine that's been used for 20 years following soft tissue or orthopedic surgical procedures. In Exparel, the bupivicaine is surrounded by tiny spheres or bubbles of fat and water. As the tiny "DepoFoam" spheres dissolve, they release the bupivicaine slowly into the surgical wound, extending the pain relief from hours to days.

Hospitals perform 24 million surgical procedures annually in which Exparel could be used, Pacira says.

Exparel will cost more than regulaor bupivicaine, both of which are typically injected into a wound just before it's closed. Pacira says surgeons and hospitals will save money overall using Exparel for post-surgical care because patients will require fewer opioid painkillers following surgery. Use of opioids is not only expensive for hospitals but it also causes significant side effects for patients, Pacira says.

Pacira's challenge is to convince hospitals that adopting Exparel to replace standard (and cheaper) bupivicaine is good for patients and for their bottom line. To make that argument, the company has commissioned health care economic studies to demonstrate Exparel's value. Additional studies are also planned.

Getting a new drug added to a hospital's so-called "formulary" can take time, and even if a new drug is added to the formulary doesn't necessarily guarantee that doctors will it. Cadence Pharmaceuticals (CADX) has found it relatively easy to convince hospitals to add its injectable acetaminophen Ofirmev to formularies but generating revenue has been much more difficult and the company's stock price has suffered for it.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
CADX $0.00 0.00%
PCRX $65.97 -1.30%
AAPL $126.88 -1.40%
FB $77.71 -1.40%
GOOG $534.50 -1.20%

Markets

DOW 18,002.07 -68.33 -0.38%
S&P 500 2,100.72 -13.77 -0.65%
NASDAQ 4,961.6030 -55.3260 -1.10%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs